Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252368 | 0.93 | ALDH1A1 (0.51) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL6922435 | 0.89 | ALDH1A1 (0.47) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL239105 | 0.86 | TDP1 (0.56) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL403033 | 0.80 | SLC18A3 (0.45) | ALDH1A1MAPTLMNAGAATDP1 | |
| SCHEMBL177098 | 0.79 | ALDH1A1 (0.51) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL177099 | 0.79 | ALDH1A1 (0.51) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL1970805 | 0.79 | ATM (0.53) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL29653738 | 0.79 | ATM (0.53) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL31570575 | 0.79 | PDE4A (0.48) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL17913158 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MAPTLMNAGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149622-A1 | WNK1 INHIBITORS | DANIA THERAPEUTICS APS (DK) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025037871-A1 | TRICYCLIC COMPOUND AND USE THEREOF AS MAT2A INHIBITOR | 에스케이바이오팜 주식회사 | 2025-02-20 | — | — | WO | disclosed |
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| WO-2012055995-A1 | TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
| US-7335777-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2008-02-26 | — | — | US | disclosed |
| US-7335777-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2008-02-26 | — | — | US | disclosed |
| US-7335777-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2008-02-26 | — | — | US | disclosed |
| EP-1613312-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA A RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2008-02-20 | — | — | EP | disclosed |
| EP-1613312-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA A RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2008-02-20 | — | — | EP | disclosed |
| US-20060148856-A1 | Benzimidazole derivatives and their use for modulating the gabaa receptor complex | ANIONA APS (DK) | 2006-07-06 | — | — | US | disclosed |
| EP-1613312-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087137-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087137-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | PTGES, PTGS1, PTGIS | ALDH1A1 263/4885HIF1A 2178/4885VCAM1 2826/4885 |
| US-20060148856-A1 | Benzimidazole derivatives and their use for modulating the gabaa receptor complex | GABRB2, GABRB1, GABRB3 | ALDH1A1 312/4885HIF1A 957/4885VCAM1 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.